Vertex Secures German Reimbursement for CRISPR Gene Therapy CASGEVY in Sickle Cell Disease and Beta Thalassemia
核心洞察
Vertex Pharmaceuticals announced a reimbursement agreement with Germany's GKV-Spitzenverband (搜索) for CASGEVY, marking the first long-term sustainable access agreement for gene therapy in sickle cell disease (搜索) and transfusion-dependent beta thalassemia (搜索) in Germany.
CASGEVY is a one-time CRISPR/Cas9 gene-edited cell therapy that edits patients' own stem cells to produce high levels of fetal hemoglobin (搜索), eliminating vaso-occlusive crises (搜索) in sickle cell disease (搜索) and reducing transfusion requirements in beta thalassemia.
Germany joins eight other countries providing reimbursement for CASGEVY, including Austria, Denmark, Italy, Saudi Arabia, UAE, UK, and the United States, expanding global access to this innovative therapy.
Vertex Pharmaceuticals announced a landmark reimbursement agreement with Germany's GKV-Spitzenverband (搜索) for CASGEVY (exagamglogene autotemcel), securing sustainable access to the CRISPR/Cas9 gene-edited therapy for eligible patients ages 12 years and older with severe sickle cell disease (搜索) or transfusion-dependent beta thalassemia (搜索).
"For the first time in Germany, a long-term, sustainable access agreement to a gene therapy has been established for people living with sickle cell disease (搜索) and transfusion-dependent beta thalassemia (搜索)," said Ludovic Fenaux, Senior Vice President, Vertex International. "This agreement represents significant progress for people living with these two devastating and life-shortening diseases."
Revolutionary CRISPR Technology
CASGEVY represents a breakthrough in gene therapy, utilizing non-viral, ex vivo CRISPR/Cas9 technology to edit patients' own hematopoietic stem and progenitor cells. The therapy targets the erythroid specific enhancer region of the BCL11A (搜索) gene through a precise double-strand break, resulting in the production of high levels of fetal hemoglobin (搜索) (HbF (搜索)) in red blood cells.
Fetal hemoglobin (搜索) is the oxygen-carrying hemoglobin naturally present during fetal development, which switches to adult hemoglobin after birth. By restoring HbF (搜索) production, CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (搜索) for patients with sickle cell disease (搜索) and transfusion requirements for patients with transfusion-dependent beta thalassemia (搜索).
Addressing Devastating Genetic Diseases
Sickle cell disease (搜索) is a debilitating, progressive, life-shortening genetic disease that affects red blood cells essential for carrying oxygen throughout the body. The clinical hallmark is vaso-occlusive crises (搜索) caused by blockages of blood vessels by sickled red blood cells, resulting in severe and debilitating pain that can occur anywhere in the body at any time. In Europe, the mean age of death for patients living with sickle cell disease is around 40 years.
Transfusion-dependent beta thalassemia (搜索) is equally serious, requiring frequent blood transfusions and iron chelation therapy throughout a person's life. Patients may experience fatigue, shortness of breath, and complications including enlarged organs, misshapen bones, and delayed puberty. In Europe, the mean age of death for patients with TDT is 50-55 years.
Complex Treatment Process
CASGEVY treatment involves a sophisticated four-step process spanning several months. First, patients receive mobilization medicines to move blood stem cells from bone marrow into the bloodstream, followed by cell collection through apheresis. The collected cells are then sent to manufacturing sites where CASGEVY is produced, a process that may take up to six months.
Before receiving the gene-edited cells, patients undergo conditioning treatment in the hospital to clear existing bone marrow cells. Finally, CASGEVY is administered through intravenous infusion, followed by a hospital stay of 4-6 weeks for monitoring recovery as the modified cells engraft.
Global Expansion of Access
With this agreement, Germany joins a growing list of countries providing reimbursement for CASGEVY, including Austria, Denmark, Italy, the Kingdom of Saudi Arabia, the United Arab Emirates, the United Kingdom, and the United States. CASGEVY is approved for eligible sickle cell disease (搜索) and transfusion-dependent beta thalassemia (搜索) patients 12 years and older by multiple regulatory bodies worldwide.
In the European Union, CASGEVY is specifically approved for patients 12 years of age and older with either severe sickle cell disease (搜索) with recurrent vaso-occlusive crises (搜索) or transfusion-dependent beta thalassemia (搜索), for whom hematopoietic stem cell transplantation is appropriate and a human leukocyte antigen matched related donor is not available.
Safety Profile and Monitoring
The most common side effects of CASGEVY include low levels of platelet cells and white blood cells during the engraftment period. Patients require careful monitoring for signs of bleeding complications and increased infection susceptibility. Healthcare providers conduct regular blood tests to monitor cell levels and determine when they return to safe ranges.
Vertex remains committed to working with government and reimbursement authorities globally to ensure sustainable access for eligible patients, marking a significant milestone in making advanced gene therapies accessible to patients with rare genetic diseases.